Resistance Training Helps Tirzepatide Users Keep Muscle While Losing Weight, Trial Finds
Adults taking tirzepatide who added regular resistance training lost less lean tissue and gained strength compared with those on the medication alone, according to a randomized trial led by University of Western Australia researchers.
By Chioma Brooks ·

Pairing the weight-loss drug tirzepatide with regular resistance training helped adults shed pounds while preserving more muscle and building strength, a new randomized trial has found.
The study, led by researchers at the University of Western Australia and published November 9 in Nature Medicine, followed 120 adults over 40 weeks. All participants received tirzepatide, and half were assigned to three resistance-training sessions per week while the rest continued their usual activities.
Tirzepatide is the active ingredient in Mounjaro and Zepbound. In the United States, Mounjaro is used to treat type 2 diabetes, while Zepbound is approved for weight management in eligible adults. The drug works on two hormone receptors involved in appetite and food intake.
The participants were men and postmenopausal women between 50 and 70 years old who had obesity or were overweight with a related health condition. None had type 2 diabetes, and both groups received general guidance on protein, fiber, and hydration.
Both groups lost roughly the same amount of weight, about 22 kilograms, or 49 pounds. But those who trained lost an average of 3.57 kilograms of lean soft tissue, compared with 4.67 kilograms in the medication-only group, a difference of approximately 1.1 kilograms.
Strength outcomes diverged as well. Upper- and lower-body strength improved in the exercise group and declined among those taking the medication alone, based on tests that included the bench press and knee extension.
Lean tissue includes muscle and other nonfat tissue, and lead investigator Prof. Danny Green said treatment should aim to maintain physical function as weight comes off. He urged doctors to build resistance exercise into treatment plans. "We now know that muscle loss can be reduced and strength increased when regular resistance training is used alongside tirzepatide treatment," Green said in a university statement.
The researchers cautioned that the trial tested a structured exercise program in a specific patient group, so its results cannot automatically be extended to other weight-loss drugs or exercise routines.
Zepbound's US prescribing information already calls for the drug to be used alongside a reduced-calorie diet and increased physical activity. The new trial offers evidence about one particular form of that activity: resistance training.
The university said Eli Lilly supplied the medication but had no role in designing, running, or evaluating the investigator-initiated trial. Several authors disclosed payments or advisory relationships with pharmaceutical or nutrition companies.






